Literature DB >> 20631450

Identification of new prognostic factors of pulmonary hypertension.

Yutaka Miura1, Yoshihiro Fukumoto, Koichiro Sugimura, Minako Oikawa, Makoto Nakano, Shunsuke Tatebe, Saori Miyamichi, Kimio Satoh, Hiroaki Shimokawa.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) still remains a serious disease, for which the plasma level of brain natriuretic peptide (BNP) and hemodynamic variables (eg, cardiac index: CI) are established prognostic factors. The aim of the present study was to identify new additional prognostic factors of the disorder to improve the management of PH. METHODS AND
RESULTS: The study cohort comprised 136 consecutive PH patients admitted to hospital from 1974 to 2008, all of whom were closely followed every 6-12 months. During the follow-up period of 53.5+/-4.5 [SEM] months, 47 patients died of cardiopulmonary causes. The patients who were initially treated with monotherapy showed improved pulmonary hemodynamics when subsequently treated with combination therapy. Multivariate analysis showed that BNP and CI were significant and independent prognostic factors in all PH patients. However, in PH patients with low CI at diagnosis, only CI improvement by PH therapy was a significant and independent prognostic factor. Indeed, the patients with low CI at diagnosis (CI <2.5) followed by subsequent normalization in response to therapy (CI > or =2.5) showed a significantly better survival compared with those without such normalization.
CONCLUSIONS: CI normalization in response to treatment is an independent new prognostic factor of PH in patients with low CI at diagnosis, suggesting the importance of intensive therapy to achieve CI normalization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631450     DOI: 10.1253/circj.cj-10-0270

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

1.  Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.

Authors:  Aravind A Menon; Sandeep Sahay; Lewis E Braverman; Harrison W Farber
Journal:  Lung       Date:  2019-11-06       Impact factor: 2.584

2.  Activation of Autophagy Induces Monocrotaline-Induced Pulmonary Arterial Hypertension by FOXM1-Mediated FAK Phosphorylation.

Authors:  Cui Zhai; Nana Zhang; Jian Wang; Meng Cao; Jing Luan; Huan Liu; Qianqian Zhang; Yanting Zhu; Yuxin Xue; Shaojun Li
Journal:  Lung       Date:  2022-09-15       Impact factor: 3.777

3.  The clinical characteristics and outcomes of patients with pulmonary hypertension in association with hyperthyroid state: A systematic review.

Authors:  Fateen Ata; Adeel Ahmad Khan; Zohaib Yousaf; Hassan Choudry; Areej Marwan Mohammed; Bilal Ahmed; Ahmed Muaaz Umer; Fareeha Khan; Dabia Hamad Sh Al Mohanadi; Emad Naem; Muhammad Zahid
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

4.  Prognostic factors in pulmonary hypertension.

Authors:  Flavia Catalina Corciova; Catalina Arsenescu-Georgescu
Journal:  Maedica (Buchar)       Date:  2012-01

5.  Role of notch signal in angiotensin II induced pulmonary vascular remodeling.

Authors:  Li-Na Qiao; Hong-Bo Xu; Kun Shi; Tong-Fu Zhou; Yi-Min Hua; Han-Min Liu
Journal:  Transl Pediatr       Date:  2013-01

Review 6.  Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course.

Authors:  Fabiana Baldi; Leonello Fuso; Eugenio Arrighi; Salvatore Valente
Journal:  Ther Clin Risk Manag       Date:  2014-10-07       Impact factor: 2.423

7.  Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension.

Authors:  Mitsushige Murata; Toshimitsu Tsugu; Takashi Kawakami; Masaharu Kataoka; Yugo Minakata; Jin Endo; Hikaru Tsuruta; Yuji Itabashi; Yuichiro Maekawa; Mitsuru Murata; Keiichi Fukuda
Journal:  Oncotarget       Date:  2016-12-27

8.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension.

Authors:  Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

9.  Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.

Authors:  Shaojun Li; Dong Han; Yonghong Zhang; Xinming Xie; Rui Ke; Yanting Zhu; Lu Liu; Yang Song; Lan Yang; Manxiang Li
Journal:  Med Sci Monit Basic Res       Date:  2016-03-09

10.  eIF2α promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats.

Authors:  Linya Guo; Yanbing Li; Ying Tian; Shaoxin Gong; Xi Chen; Tianhong Peng; Aiping Wang; Zhisheng Jiang
Journal:  Drug Des Devel Ther       Date:  2019-08-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.